The forecast for systemic hormonal preparations sales in Japan (excluding sex hormones and insulins) shows steady growth from 2024 to 2028, beginning at a volume forecast of $3.06 billion in 2024. The year-on-year growth rate is projected to average around 4.1%, with a steady upward trajectory that indicates a Compound Annual Growth Rate (CAGR) of approximately 4.09% over the five-year period.
Future trends to watch:
- Aging population in Japan driving demand for hormone therapies
- Innovations in pharmaceutical formulations and delivery methods
- Economic and regulatory changes impacting healthcare spending
- Increasing focus on personalized medicine
